Please proceed with registration and ordering once you have received your approval letter and promotional code from GSC.
1: AkaRx Inc. Doptelet (avatrombopag) FDA Product Monograph. Reference ID: NDA210238, 07/2024.
2: Alenius M, et al. Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting. J Psychiatr Res. 2008;42(11),884–893.
3: Alkermes Inc. Aristada (aripiprazole lauroxil) FDA Product Monograph. Reference ID: NDA207533, 12/2023.
4: Amneal Pharmaceuticals NY LLC. Brexpiprazole FDA Product Monograph. Reference ID: ANDA213562, 03/2024.
5: Amstutz U, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clin Pharmacol Ther. 2018;103(2):210-216.
6: Avanir Pharmaceuticals, Inc. Nuedexta (dextromethorphan hydrobromide and quinidine sulfate) FDA Product Monograph. Reference ID: 4446950, 06/2019
7: Axsome Therapeutics, Inc. Auvelity (dextromethorphan hydrobromide and bupropion hydrochloride) FDA Product Monograph. Reference ID: 5376564, 08/2022.
8: Bakker PR, et al. Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions. Mol Psychiatry. 2008;13(5),544–556.
9: Bell GC, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron. Clin Pharmacol Ther. 2017;102(2):213-218.
10: Biogen Inc. Aduhelm (aducanumab-avwa) FDA Product Monograph. Reference ID: 4807032, 06/2021.
11: Birdwell KA, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing. Clin Pharmacol Ther. 2015;98(1):19-24.
12: Bousman CA, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68.
13: Brown JT, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy. Clin Pharmacol Ther. 2019;106(1):94-102.
14: Cadila Pharmaceuticals Limited. Fluoxetine FDA Product Monograph. Reference ID: ANDA206993, 07/2024.
15: Cooper-DeHoff RM, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021.
16: Crews KR, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy. Clin Pharmacol Ther. 2021;110(4):888-896.
17: Desta Z, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy. Clin Pharmacol Ther. 2019;106(4):726-733.
18: Duarte JD, et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy. Clin Pharmacol Ther. 2024;116(4):939-947.
19: Dutch Pharmacogenetics Working Group (DPWG). Pharmacogenetic Recommendation Text. Jun 2023. https://www.knmp.nl/dossiers/farmacogenetica
20: Eisai Inc. Leqembi (lecanemab-irmb) FDA Product Monograph. Reference ID: BLA761269, 01/2023.
21: Gammal RS, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing. Clin Pharmacol Ther. 2016;99(4):363-369.
22: Gammal RS, et al. Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype. Clin Pharmacol Ther. 2023;113(5): 973-985.
23: Goetz MP, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy. Clin Pharmacol Ther. 2018;103(5):770-777.
24: Gonsalves SG, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the Use of Potent Volatile Anesthetic Agents and Succinylcholine in the Context of RYR1 or CACNA1S Genotypes. Clin Pharmacol Ther. 2019;105(6):1338-1344.
25: Ham AC, et al. CYP2C9 Genotypes Modify Benzodiazepine-Related Fall Risk: Original Results from Three Studies With Meta-Analysis. J Am Med Dir Assoc. 2017;18(1):88.e1-88.e15.
26: Harmony Biosciences, LLC. Wakix (pitolisant) FDA Product Monograph. Reference ID: NDA211150, 12/2022.
27: Hicks JK, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44.
28: Ipsen Biopharmaceuticals Inc. Onivyde (irinotecan) FDA Product Monograph. Reference ID: NDA207793, 02/2024.
29: Johnson JA, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404.
30: Karnes JH, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update. Clin Pharmacol Ther. 2021;109(2):302-309.
31: Lee CR, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update. Clin Pharmacol Ther. 2022;112(5):959-967.
32: Lima JJ, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther. 2021;109(6):1417-1423.
33: Lundbeck Pharmaceuticals LLC. Onfi (clobazam) FDA Product Monograph. Reference ID: NDA202067/ NDA203993, 03/2024.
34: Martin MA, et al. Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing. Clin Pharmacol Ther. 2012;91(4):734-738.
35: McDermott JH, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for the Use of Aminoglycosides Based on MTRNR1 Genotype. Clin Pharmacol Ther. 2022;111(2):366-372.
36: Moriyama B, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy. Clin Pharmacol Ther. 2017;102(1):45-51.
37: Muir AJ, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens. Clin Pharmacol Ther. 2014;95(2):141-146.
38: Mulder H, et al. The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia. J Clin Psychopharmacol. 2007;27(4),338–343.
39: Mulder H, et al. The association between HTR2C polymorphisms and obesity in psychiatric patients using antipsychotics: a crosssectional study. Pharmacogenomics J. 2007;7(5),318–324.
40: Novartis Pharmaceuticals Corporation. Promacta (eltrombopag) FDA Product Monograph. Reference ID: 4599937, 04/2020.
41: Pfizer Laboratories Div Pfizer Inc. Cibinqo (abrocitinib) FDA Product Monograph. Reference ID: NDA213871, 12/2023.
42: Pharmacia & Upjohn Company LLC. Camptosar (irinotecan) FDA Product Monograph. Reference ID: NDA020571, 01/2022.
43: Phillips EJ, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update. Clin Pharmacol Ther. 2018;103(4):574-581.
44: Relling MV, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther. 2019;105(5):1095-1105.
45: Risselada AJ, et al. Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics: a replication study. Pharmacogenomics J. 2012;12(1),62–67.
46: Robinson KM, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2B6 Genotype and Methadone Therapy. Clin Pharmacol Ther. 2024;116(4):932-938.
47: Saito Y, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update. Clin Pharmacol Ther. 2016;99(1):36-37.
48: ScieGen Pharmaceuticals Inc. Aripiprazole FDA Product Monograph. Reference ID: ANDA207240, 08/2024.
49: Shionogi Inc. Mupleta (lusutrombopag) FDA Product Monograph. Reference ID: NDA210923, 10/2020.
50: The Clinical Pharmacogenetics Implementation Consortium. CPIC Guideline for Thiopurines and TPMT and NUDT15 – Updates since publication Mar 2024. https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/
51: Theken KN, et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal AntiInflammatory Drugs. Clin Pharmacol Ther. 2020;108(2):191-200.
52: US Food and Drug Administration. Table of Pharmacogenetic Associations: Section 1: Pharmacogenetic associations for which the data support therapeutic management recommendations. Section 2: Pharmacogenetic associations for which the data indicate a potential impact on safety or response. Section 3: Pharmacogenetic associations for which the data demonstrate a potential impact on pharmacokinetic properties only. 2022. https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogeneticassociations
53: Whirl-Carrillo M, et al. Pharmacogenomics Knowledge for Personalized Medicine. Clin Pharmacol Ther. 2012;92(4):414-417. PharmGKB Data Usage Policy: https://www.pharmgkb.org/page/dataUsagePolicy. The only changes from the original PharmGKB content included in this report of record are related to formatting (adding a header).
54: Whirl-Carrillo M, Huddart R, et al. An Evidence-Based Framework for Evaluating Pharmacogenomics Knowledge for Personalized Medicine. Clin Pharmacol Ther. 2021;110(3):563-572. PharmGKB Data Usage Policy: https://www.pharmgkb.org/page/dataUsagePolicy. The only changes from the original PharmGKB content included in this report of record are related to formatting (adding a header).
55: Young RM, et al. Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele. Br J Psychiatry. 2004;185,147–151
56: Zai CC, et al. Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients. Mol Psychiatry. 2007;12(9),794–795.